Pharma company to expand business in Europe with new subsidiary incorporation in Poland

DSIJ Intelligence-1Categories: Multibaggers, Penny Stocks, Trendingprefered on google

Pharma company to expand business in Europe with new subsidiary incorporation in Poland

The stock is up by 7.8 per cent from its 52-week low of Rs 22.33 per share and has given multibagger returns of 197 per cent in 2 years.

Sudarshan Pharma Industries Ltd has successfully incorporated its wholly-owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, in Warsaw, Poland. Following Board approval on February 19, 2025, the company subscribed to 100 shares at PLN 50 each, totalling PLN 5,000 (approximately Rs 1,30,000). This strategic move, executed via cash consideration pending RBI approval, establishes a 100% shareholding to facilitate market expansion within the European region.

The new subsidiary will focus on the manufacture of basic chemicals, fertilisers, plastics and synthetic rubber, alongside the wholesale of pharmaceuticals and coSMEtics. As a newly formed entity with no prior turnover, it serves as a vehicle for Sudarshan Pharma to enlarge its customer base. The incorporation complies with SEBI Listing Regulations and Polish law, positioning the company to strengthen its industrial footprint in the international chemical and agrochemical sectors.

Not every stock is a winner—but some multiply wealth manifold. DSIJ's multibagger Pick filters these rare gems through rigorous analysis & decades of expertise. Get the Full Brochure

About the Company

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East and North Africa.

According to the Quarterly Results, the net sales increased by 16 per cent to Rs 168.87 crore in Q2FY26 compared to Q2FY25. The company reported a net profit of Rs 3.87 crore in Q2FY26. For half-yearly results, the net sales increased by 38 per cent to Rs 314.13 crore and net profit increased by 68 per cent to Rs 7.83 crore in H1FY26 compared to H1FY25. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24.

The company has a market cap of over Rs 500 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years. In September 2025, FIIs bought 31,44,000 shares and increased their stake by 20.79 per cent compared to June 2025. The stock is up by 7.8 per cent from its 52-week low of Rs 22.33 per share and has given multibagger returns of 197 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.